Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07022977 · ClinicalTrials.gov registry record · Phase 1

A Study of MET233 in Individuals With Obesity or Overweight

A Phase 1 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
120
Enrollment target
1
Study location

NCT07022977 is a Phase 1 study of Obesity and Overweight that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants, below the 461-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07022977, a Phase 1 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET233 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET233 or placebo. In Part C, participants will receive once-weekly doses of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.

Conditions Studied

Obesity and Overweight

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL MET233

Study Locations (1)

California

  • MET233 Research Site 001 - Cypress

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-11-20
Est. Completion 2026-04-15
Phase Phase 1

Sponsor

Metsera, a wholly owned subsidiary of Pfizer

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07022977

The ClinicalTrials.gov registry entry for NCT07022977 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 461-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (74% lower). The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07022977 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07022977 about?

NCT07022977 is a clinical study titled "A Study of MET233 in Individuals With Obesity or Overweight". The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose...

What is the current status of trial NCT07022977?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-11-20. Estimated completion is 2026-04-15.

What conditions does trial NCT07022977 study?

This clinical trial studies the following conditions: Obesity and Overweight.

What interventions are being tested in trial NCT07022977?

The interventions under investigation include: Placebo (BIOLOGICAL), MET233 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07022977?

This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07022977 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity and Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.